KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Net Margin: 2012-2025

Historic Net Margin for Sarepta Therapeutics (SRPT) over the last 11 years, with Jun 2025 value amounting to -73.94%.

  • Sarepta Therapeutics' Net Margin fell 7581.00% to -73.94% in Q2 2025 from the same period last year, while for Jun 2025 it was -13.64%, marking a year-over-year decrease of 1683.00%. This contributed to the annual value of 12.36% for FY2024, which is 5548.00% up from last year.
  • According to the latest figures from Q2 2025, Sarepta Therapeutics' Net Margin is -73.94%, which was down 406.55% from 24.12% recorded in Q4 2024.
  • Sarepta Therapeutics' 5-year Net Margin high stood at 24.12% for Q4 2024, and its period low was -203.85% during Q1 2023.
  • Over the past 3 years, Sarepta Therapeutics' median Net Margin value was 1.87% (recorded in 2024), while the average stood at -27.30%.
  • As far as peak fluctuations go, Sarepta Therapeutics' Net Margin tumbled by 15,403bps in 2023, and later soared by 21,269bps in 2024.
  • Over the past 5 years, Sarepta Therapeutics' Net Margin (Quarterly) stood at -60.55% in 2021, then spiked by 1,804bps to -42.51% in 2022, then soared by 5,398bps to 11.47% in 2023, then soared by 1,264bps to 24.12% in 2024, then tumbled by 7,581bps to -73.94% in 2025.
  • Its Net Margin stands at -73.94% for Q2 2025, versus 24.12% for Q4 2024 and 7.28% for Q3 2024.